Enjoy complimentary customisation on priority with our Enterprise License!
Technavio’s market research analysis identifies the early onset of disease symptoms that increases the demand for Huntington’s disease (HD) therapeutics as one of the primary growth factors for the Huntington’s disease therapeutics market. HD is equally prevalent in both males and females and affects people irrespective of their ethnicity. The disease symptoms may appear anytime in the individual’s life and the etiology is genetic. The person who inherits the mutated genes from their affected parents will probably suffer from the disease sometime in their lifetime. According to our market research analysts, this market will grow steadily at a CAGR of around 15% by 2021.
The advancements in science and the introduction of nanotechnologies has resulted in modern techniques such as bioinformatics, molecular targeting, nanotechnology, and personalized medicines that has facilitated drug development to cure neurodegenerative disorders. The advancements have resulted in the better understanding of the pathogenesis of disease at genetic and molecular level that further results in the discovery of new targets for therapy and disease modifying drugs. Intensive R&D has resulted in the identification of an enzyme that can potentially reverse the progression of HD. This research analysis identifies the advancements in biomedical sciences as one of the key trends behind the growth of the Huntington’s disease therapeutics market.
The Huntington’s disease therapeutics market is fragmented due to the presence of several large and small vendors who are focusing on consolidating their market shares through strategic alliances and acquisitions. Government support in terms of granting orphan drug designation, major patent expiries, and the rising awareness about HD, are major factors that play a significant role in the performance of the vendors in this marketspace.
The leading vendors in the market are -
The other prominent vendors in the market are Intellect Neurosciences, Horizon Pharma, Sangamo Therapeutics, and Vertex Pharmaceuticals.
Owing to their effect on reversible depletion of monoamines including dopamine, Antidopaminergics agents are primarily suitable to treat chorea, which is the most common problem associated with HD. Tetrabenazine (TBZ) is primarily used for pharmacological and the symptomatic treatment of chorea associated with HD due to their therapeutic efficacy.
The Americas is witnessing increasing incidences of HD. The availability of increased patient pool and the rise in government initiatives boost the research and development of novel therapeutics for the treatment of HD. The rising investments towards the launch of new drugs for the treatment of chorea will positively influence the growth of the Huntington’s disease therapeutics market in this region.
Technavio also offers customization on reports based on specific client requirement
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: HD: An introduction
PART 06: Market landscape
PART 07: Pipeline
PART 08: Market segmentation by drug-class
PART 09: Geographical segmentation
PART 10: Decision framework
PART 11: Drivers and challenges
PART 12: Market trends
PART 13: Vendor landscape
PART 14: Key vendor analysis
PART 15: Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.